4basebio said this week that its previously announced share buyback offer was oversubscribed, and the company will now proceed to acquire the maximum amount of shares tendered in the framework of the public offer, up to 5.2 million shares, for a final purchase price of €1.85 per share. The company will announce the exact number of shares that will be acquired once the allocation quota has been determined. The settlement of the offer is expected to take place on Feb. 24.
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.